Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Up 6.0% in January

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 6,000,000 shares, an increase of 6.0% from the December 31st total of 5,660,000 shares. Currently, 31.2% of the shares of the company are sold short. Based on an average daily trading volume, of 250,800 shares, the days-to-cover ratio is currently 23.9 days.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter worth approximately $236,000. SG Americas Securities LLC boosted its holdings in Dianthus Therapeutics by 104.0% during the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company's stock worth $242,000 after buying an additional 4,506 shares in the last quarter. Quest Partners LLC grew its position in Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company's stock worth $31,000 after buying an additional 1,124 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Dianthus Therapeutics by 142.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company's stock valued at $4,543,000 after buying an additional 97,362 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its position in shares of Dianthus Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 13,939 shares of the company's stock valued at $382,000 after acquiring an additional 7,854 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Trading Down 7.2 %

NASDAQ:DNTH traded down $1.77 during midday trading on Thursday, hitting $22.96. 384,597 shares of the stock were exchanged, compared to its average volume of 262,117. The company has a market capitalization of $679.62 million, a price-to-earnings ratio of -9.18 and a beta of 1.72. Dianthus Therapeutics has a one year low of $18.34 and a one year high of $33.77. The business has a 50-day moving average price of $23.06 and a two-hundred day moving average price of $25.85.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. Sell-side analysts forecast that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Oppenheimer boosted their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday, November 11th. Raymond James upgraded shares of Dianthus Therapeutics to a "moderate buy" rating in a research note on Thursday, December 12th. Finally, TD Cowen began coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They set a "buy" rating for the company. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of "Buy" and a consensus price target of $46.43.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.